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expressed in tissues like the kidney or vascular endothe-
lium, where it executes important physiological func-
tions. COX-2-dependent formation of prostanoids not 
only results in the mediation of pain or infl ammatory 
signals but also in the maintenance of vascular integrity. 
Especially prostacyclin (PGI 2 ), which exerts vasodilatory 
and antiplatelet properties, is formed to a signifi cant ex-
tent by COX-2, and its levels are reduced to less than half 
of normal when COX-2 is inhibited. This review outlines 
the rationale for the development of selective COX-2 in-
hibitors and the pathophysiological consequences of se-
lective inhibition of COX-2 with special regard to vasoac-
tive prostaglandins. It describes coxibs that are current - 
ly available, evaluates the current knowledge on the risk 
of atherothrombotic events associated with their intake 
and critically discusses the consequences that should be 
drawn from these insights. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 The spectacular, worldwide withdrawal of Vioxx (ro-
fecoxib) from the market, followed by a similar warning 
about Celebrex (celecoxib), has initiated legal and com-
mercial sequelae and has also induced great uncertainty 
among patients and physicians. Patients experienced a 
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 Abstract 
 Selective inhibitors of cyclooxygenase-2 (COX-2, ‘cox-
ibs’) are highly effective anti-infl ammatory and analgesic 
drugs that exert their action by preventing the formation 
of prostanoids. Recently some coxibs, which were de-
signed to exploit the advantageous effects of non-steroi-
dal anti-infl ammatory drugs while evading their side ef-
fects, have been reported to increase the risk of myo - 
cardial infarction and atherothrombotic events. This 
has led to the withdrawal of rofecoxib from global mar-
kets, and warnings have been issued by drug authorities 
about similar events during the use of celecoxib or valde-
coxib/parecoxib, bringing about questions of an inherent 
atherothrombotic risk of all coxibs and consequences 
that should be drawn by health care professionals. These 
questions need to be addressed in light of the known ef-
fects of selective inhibition of COX-2 on the cardiovascu-
lar system. Although COX-2, in contrast to the cyclooxy-
genase-1 (COX-1) isoform, is regarded as an inducible 
enzyme that only has a role in pathophysiological pro-
cesses like pain and infl ammation, experimental and 
clinical studies have shown that COX-2 is constitutively 
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loss of confi dence in medical professionals and in the 
pharmaceutical industry, because there was speculation 
that the atherothrombotic risk of these drugs could have 
been known before  [1, 2] . Among health care profession-
als, there remains uncertainty especially regarding the 
question of whether the remaining selective COX-2 in-
hibitors which are still available on the market hold sim-
ilar risks, as far less clinical data about these drugs are  at 
hand than for rofecoxib. 
 Moreover, some new, highly selective COX-2 inhibi-
tors are being launched. To avoid wrongful testing of 
these drugs, which are highly effective and well appreci-
ated in patients, it will be of critical importance for the 
pharmaceutical industry in charge as well as for prescrib-
ing physicians that these launches will be accompanied 
by responsible marketing strategies that also inform about 
potential side effects even if there are no conclusive data 
from large clinical studies yet. 
 However, the question of whether the side effects ob-
served for rofecoxib, and more recently also for celecoxib 
and valdecoxib/parecoxib, represent a class effect of these 
drugs, or whether this was an effect that was specifi c for 
rofecoxib  [3] , which would not be caused by other coxibs, 
needs to be examined on the basis of the biological role 
of cyclooxygenase isoforms, of their products, and of the 
mode of action of inhibitors of these enzymes. 
 In the following, we will highlight the physiological 
role of cyclooxygenases and prostaglandins in vascular 
biology and shed light on some widespread pathophysi-
ological assumptions that have formed the rationale for 
the development of selective inhibitors of COX-2. We 
will then focus on the effectiveness of selective COX-2 
inhibitors and draw comparisons between non-specifi c 
inhibition of cyclooxygenases and specifi c inhibition of 
COX-2. We will outline the pathophysiological conse-
quences of selective inhibition of COX-2 for vascular 
prostanoid formation and discuss the potential implica-
tions of these effects for atherothrombosis according to 
clinical and experimental knowledge. Finally, we will dis-
cuss the relevance of these insights for indications, poten-
tial advantages and potential risks of selective COX-2 
inhibitors other than rofecoxib that are clinically ap-
proved or currently being developed. 
 Cyclooxygenase Isoforms and Products 
 The enzyme referred to as cyclooxygenase uses arachi-
donic acid, which is liberated from membrane-bound 
phospholipids through phospholipase A 2 , as a substrate 
to generate the endoperoxide prostaglandin G 2  (PGG 2 ). 
By the same enzymatic complex, PGG 2  is further bio-
transformed to another endoperoxide, prostaglandin H 2  
(PGH 2 )  [4–6] . Thus, a more correct terminology refers to 
this enzymatic complex as prostaglandin H synthase 
(PGHS), thereby describing an enzyme that possesses two 
catalytic moieties, that of a cyclooxygenase (generating 
the endoperoxide structure of PGG 2 ) and that of a per-
oxidase (generating PGH 2  from PGG 2 ), although the 
widely used description cyclooxygenase usually refers to 
the whole complex of PGHS  [5] . This simplifi cation re-
fl ects the fact that many well-known non-steroidal anti-
infl ammatory drugs (NSAID) inhibit the  activity of the 
enzyme by preventing access of arachidonic acid to the 
catalytic site of the cyclooxygenase located inside a hy-
drophobic channel, which is formed by PGHS, without 
affecting the peroxidase activity, which is located outside 
this hydrophobic channel  [6, 7] . For matters of simplic-
ity, we will retain the biochemically simplifi ed terminol-
ogy of referring to PGHS as ‘cyclooxygenase’. 
 COX-2 is only one of at least two different isoforms of 
cyclooxygenase. A recent report even describes a third 
isoform, ‘COX-3’, which appears to be a variant of COX-
1 expressed in dog brain, and has been discussed to be the 
target of acetaminophen  [8, 9] . As there is no evidence 
for a role of this isoform, or other yet unidentifi ed COX 
isoforms in the cardiovascular system, we will confi ne to 
the two well-characterized isoforms, COX-1 and COX-2, 
in this overview. 
 Following the production of PGH 2 , a second enzymat-
ic process is needed to ultimately form the different bio-
logically active prostanoids. This step is not catalyzed by 
PGHS/cyclooxygenase any more, but by tissue-specifi c 
enzymes, which all use PGH 2  as substrates  [10] . These 
enzymes show some specifi city with respect to the tissue 
they are expressed in and also generate specifi c prostanoid 
products, which also determine the name of the enzyme. 
Thus there are prostaglandin I 2  (PGI 2  or prostacyclin) 
synthase, a thromboxane A 2  (TxA 2 ) synthase, and pros-
taglandin D 2 , E 2 , or F 2  synthases  [10] . Like cyclooxygen-
ases, they are widely expressed throughout the human 
body and have numerous functions in the vascular system 
( fi g. 1 summarizes the biochemical pathways from ara-
chidonic acid liberation to the production of pros-
tanoids). 
 Inhibition of cyclooxygenases results in decreased sub-
strate availability for such tissue-specifi c prostanoid syn-
thases and subsequently decreases the production of the 
specifi c prostanoid. Little is known as to whether any of 
the cyclooxygenase isoforms shows preference of associa-
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tion with any of the downstream prostanoid synthases in 
general  [4, 6, 10] . The association of a cyclooxygenase 
with a prostanoid synthase, which is decisive for the for-
mation of a specifi c prostanoid from arachidonic acid, 
seems to be determined by the tissue of interest and by 
the specifi c pathophysiological situation  [10] . In platelets 
for example, which only contain the COX-1 isoform, the 
major PGH 2 -metabolizing isomerase coupled to COX-1 
is TxA 2  synthase, which leads to the result that the major 
arachidonic acid product of cyclooxygenase activity in 
platelets is TxA 2   [10 ,  11] . As platelets as well as vascular 
smooth muscle cells express TxA 2  receptors (TP recep-
tors), the release of TxA 2  from platelets results in platelet 
aggregation ( fi g. 2 ) and to a lesser extent in vasoconstric-
tion  [12] . When platelet COX-1 is inhibited by NSAID 
or by acetylsalicylic acid (aspirin), the resulting inhibition 
of TxA 2  mediates the desired antiplatelet effect ( fi g. 2, 3 ). 
Thus, aspirin was the fi rst and remains the most impor-
tant substance counteracting platelet aggregation. How-
ever, as NSAID or aspirin do not act directly on TxA 2  
synthase, they also inhibit any other cyclooxygenase they 
reach, independent of the isomerase to which these cyclo-
oxygenases may be coupled. Thus, numerous other phys-
iological effects result because COX-1 or COX-2 enzymes 
may be inhibited in any tissue. However, some special 
considerations need to be mentioned with respect to as-
pirin. First, in contrast to many other NSAID, aspirin 
binds irreversibly to cyclooxygenase  [13] . Second, the 
dosing of aspirin has an important role, because ‘low-dose 
aspirin’ only effectively inhibits platelet cyclooxygenase 
activity; although a single dose of only 100 mg/day al-
ready shows an inhibitory effect on COX-1, it is further 
increased by repetition of this dose, and low-dose aspirin 
ultimately blocks TxA 2  synthesis through accumulation 
in platelets  [13] . In nucleate cells, this accumulation 
would be overcome by rapid novel synthesis of cyclooxy-
genases, but platelets – being anucleate structures – can-
not suffi ciently resynthesize cyclooxygenase, so the in-
hibitory effect of aspirin can only be reversed by novel 
platelet synthesis from megakaryocytes. In contrast, 
whereas clinically used doses of other NSAID also have 
impact on the  activity of the enzyme, these drugs do not 
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 Fig. 1. Biochemical pathway leading from 
arachidonic acid to the formation of vaso-
active prostanoids. Following liberation of 
arachidonic acid from membrane phospho-
lipids, which is dependent on phospho-
lipase A 2  activity, PGHS competes with cy-
tochrome P 450  enzymes and lipoxygenase 
for further metabolism of AA. PGHS con-
tains a cyclooxygenase and peroxidase moi-
ety and produces PGH 2 , which needs to be 
further metabolized by tissue-specifi c en-
zymes (prostanoid synthases) to form the 
specifi c prostanoids PGI 2,  TxA 2 , PGD 2 , 
PGE 2  and   PGF 2  . They all act on specifi c 
receptors. The most important prostano - 
ids for vascular function are PGI 2  and 
TxA 2 . EETs   = Epoxyeicosatrienoic acids; 
HETEs = hydroxyeicosatetraenoic acids; 
HODEs = hydroxyoctadecadienoic acids; 
DP = prostaglandin D 2  receptor; EP = pros-
taglandin E 2  receptor; IP = prostacyclin re-
ceptor; FP = prostaglandin F 2  receptor;
TP = prostaglandin T 2  receptor. 
 COX-2 Inhibitors and Myocardial 
Infarction 
 J Vasc Res 2005;42:312–324 315
bind irreversibly and usually dissociate from their bind-
ing sites at cyclooxygenase  [14] . Thus low-dose aspirin 
only effectively inhibits platelet COX-1 activity (and re-
sulting TxA 2  synthesis), whereas NSAID inhibit all cyclo-
oxygenases (and the resulting formation of other pros-
tanoids), but only do so reversibly. 
 But why do higher doses of aspirin (or NSAID) not 
result in more effective inhibition of platelet aggregation? 
To understand this phenomenon, another vascular cyclo-
oxygenase metabolite with importance for platelet activ-
ity comes into focus. This metabolite, prostacyclin (PGI 2 ), 
is a potent platelet inhibitor and is formed in intact vas-
cular endothelium through cyclooxygenase coupled to 
PGI 2  synthase. Whereas repeated delivery of low doses 
of aspirin has little effect on immediate or long-term cy-
clooxygenase activity in the endothelium due to the afore-
mentioned transcriptional novel synthesis of cyclooxy-
genases and because endothelial COX-2 has limited sen-
sitivity to drug  [13, 14] , high doses of aspirin or NSAID 
have similar effects on endothelial PGI 2  and platelet 
TxA 2  synthesis, thus theoretically exerting antithrombot-
ic as well as prothrombotic effects ( fi g. 3 ). This circum-
stance, the limited time span and the reversibility of 
NSAID binding to cyclooxygenases form the pharmaco-
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 Fig. 2. Effect of platelet-active prostanoids 
on platelet function.  A Under physiological 
conditions, prostanoids infl uence platelets 
(PLT) through G-protein-coupled pros-
tanoid receptors. PGI 2  released from the 
vascular endothelium (EC) activates IP re-
ceptors and thus inhibits platelet activation 
by increasing cAMP levels, which prevents 
intracellular calcium release and decreases 
granule secretion and fi brinogen receptor 
activation (GPIIb/IIIa). The release of PGI 2  
from the endothelium depends on both, 
COX-1 and COX-2. TxA 2  is released main-
ly by activated platelets and further aug-
ments platelet calcium levels, granule secre-
tion and GPIIb/IIIa activation through TP 
receptors.  B In atherosclerosis, the situation 
may change dramatically, because the re-
lease of other endothelial autacoids, which 
decisively contribute to the antiplatelet 
properties of physiological endothelium, 
may be decreased. In addition, subendothe-
lial accumulation of macrophages (MØ) 
may participate in PGI 2  formation, and 
cyclooxygenases (especially COX-1) may 
now contribute to vascular levels of TxA 2 . 
EDHF = Endothelium-derived hyperpo-
larizing factor; IP = prostacyclin receptor; 
TP = prostaglandin T 2  receptor. 
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logical basis for several observations reporting that 
NSAID are not as effective as low-dose aspirin in inhibit-
ing platelet aggregation  [15, 16] .  
 These exemplary considerations are complicated by 
the fact that cyclooxygenase isoforms are differentially 
expressed and regulated throughout the vascular system. 
We have mentioned earlier that platelets only contain the 
COX-1 isoform. Moreover, COX-1 is expressed almost 
ubiquitously, and is therefore regarded as a housekeeping 
enzyme  [17, 18] , whereas the expression of COX-2 seems 
to be more regulated. Traditionally, COX-2 is appreci-
ated by most practicing physicians to be a strictly induc-
ible enzyme, which is upregulated upon stimulation with 
proinfl ammatory mediators such as cytokines, growth 
factors, lipopolysaccharides (LPS) or even by prostanoids 
themselves in cells that participate in infl ammatory pro-
cesses, e.g. macrophages, monocytes or other cells  [19, 
20] . However, the situation is more complicated, because 
there is evidence for COX-2 being constitutively ex-
pressed in a variety of tissues, and in some of these tissues 
important physiological functions have been attributed 
to COX-2-derived prostanoids. Constitutive expression 
or physiological roles for COX-2 have been described in 
gastric tissue of rats, rabbits and humans  [21, 22] , in dif-
ferent functional tissues of human kidney  [23] , in uterine 
epithelium  [24] , human myometrium and fetal mem-
branes  [25, 26] , in the eye  [27] and in the brain  [28] . The 
constitutive expression of COX-2 is of special importance 
with regard to cells of the vascular system. First, there 
have been reports about COX-1 being inducible  [29, 30] , 
bringing about doubts about the hypothesis of a house-
keeping or inducible enzyme. Second, it is now well rec-
ognized that COX-2 is constitutively expressed in some 
cells of the vascular system, e.g. endothelial cells, or cells 
of the renal medulla, renal vasculature or the macula den-
sa, and participates in the regulation of vessel function 
through paracrine or autocrine release of certain pros-
tanoids  [6, 20] . Moreover, it has been shown that COX-2 
constitutively binds to PGI 2  synthase in endothelial cells 
 [31] , and, as will be outlined below, numerous data sug-
gest that it is a physiological source of PGI 2  in vivo. Al-
though most prostanoids may be produced by vascular 
cyclooxygenases under certain conditions and then po-
tentially participate in the regulation of vascular function 
 [5, 32, 33] , PGI 2  and the aforementioned TxA 2  (produced 
mainly from platelets) are the most important prostanoids 
in the regulation of physiological vascular homeostasis 
having opposing effects on platelet function. 
 In addition to different expression patterns of cyclo-
oxygenase isoforms, their specifi c associations with the 
PGH 2 -metabolizing prostanoid synthases are likely to be 
of high importance for vascular prostanoid formation, 
although such specifi c interaction is only well understood 
for COX-1 coupling to TxA 2  synthase in platelets. 
 In summary, in vivo, there is a fi ne-tuned balance be-
tween certain prostanoids produced by specifi c coupling 
of cyclooxygenases with tissue-dependent prostanoid 
synthases which is infl uenced by the differential expres-
sion of cyclooxygenase isoforms. For vascular biology and 
thrombosis, the resulting effects on platelet-activating 
TxA 2  and platelet-inhibitory PGI 2  are of crucial impor-
tance. Their balance is altered by any drug targeted at 
cyclooxygenases. 
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 Fig. 3. Infl uence of low-dose aspirin, non-selective cyclooxygenase 
inhibition (NSAID, high-dose aspirin) or selective inhibitors of 
COX-2 on the vascular balance of prostanoids regarding platelet 
activity and thus thrombosis. The effects of the respective drugs on 
vascular prostanoid formation and on platelets are depicted sche-
matically. As the in vivo situation is far more complicated, this 
schematic panel only partly refl ects a schematic of a physiological 
vascular situation. Whereas low-dose aspirin selectively inhibits 
TxA 2  formation in platelets and thus lowers systemic TxA 2  levels, 
NSAID (or high-dose aspirin) inhibit cyclooxygenases non-specifi -
cally and thus also decrease PGI 2  levels independent of the source. 
As it is now clear that COX-2 is constitutively expressed in the en-
dothelium and kidney and signifi cantly contributes to systemic 
PGI 2  formation even in healthy individuals, selective inhibitors of 
COX-2 decrease systemic levels of PGI 2 , without altering TxA 2 , 
resulting in enhanced platelet activation. 
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 Development, Effi cacy and Pharmacology of 
Selective COX-2 Inhibitors 
 Because of the assumption that COX-1 is responsible 
for the production of physiological prostanoids that also 
mediate cytoprotection in gastric epithelium, whereas 
COX-2 was supposed to be the strictly inducible isoform 
mediating infl ammation, selective inhibitors of COX-2 
were developed. This has led to the assumption that the 
anti-infl ammatory effects of NSAID are solely due to in-
hibition of prostanoid production by the inducible, ‘in-
fl ammatory’ COX-2, whereas the side effects of these 
non-specifi c cyclooxygenase inhibitors are mediated 
through the inhibition of physiological prostanoid pro-
duction mediated by COX-1. It appeared logical that se-
lective inhibitors of COX-2 should bring about the ad-
vantages of NSAID without their side effects. 
 Initial experience with rofecoxib and celecoxib – the 
two selective inhibitors of COX-2 that were developed 
fi rst – was highly encouraging, as they proved at least one 
part of the hypothesis by being as effective in fi ghting in-
fl ammation and pain as other NSAID  [34–37] . Soon stud-
ies were published that aimed at demonstrating that se-
lective inhibitors of COX-2 were also superior to NSAID 
in terms of gastrointestinal side effects. At fi rst, such evi-
dence was derived from smaller endoscopic studies, 
which often proved the hypothesis  [38, 39] . The fi rst ran-
domized clinical trial showing superiority of a selective 
COX-2 inhibitor was the VIGOR trial, which compared 
rofecoxib vs. naproxen for occurrence of gastrointestinal 
toxicity among 8,076 patients suffering from rheumatoid 
arthritis  [40] . The second large clinical trial designed at 
proving this superiority of selective COX-2 inhibitors, 
the CLASS trial, compared celecoxib with diclofenac or 
ibuprofen in the treatment of arthritis  [41] . Although 
showing similar effi ciency, celecoxib failed to prove su-
perior to NSAID in terms of prevention of the primary 
endpoint, which was overall occurrence of ulcers and ero-
sions, but showed a statistically signifi cant advantage in 
terms of the secondary endpoint, complicated and symp-
tomatic ulcers  [41] . Following the initial success of cele-
coxib and rofecoxib, which in 2003 accounted for about 
75% of sales of the market for NSAID in the US  [42] , a 
race for the development of new, even more specifi c se-
lective inhibitors of COX-2 with improved pharmacoki-
netics began and led to the production of drugs like valde-
coxib (or its prodrug parecoxib for parenteral use), etori-
coxib (only approved in some European countries), or 
lumiracoxib, which was approved in the United King-
dom in September 2004 (the manufacturer has currently 
halted the application for approval of the European Med-
icines Agency for European Union countries for lumira-
coxib).  
 These drugs differ not only chemically but also in 
terms of selectivity for COX-2. Whereas rofecoxib and 
etoricoxib, both being sulfonyls, show high oral bioavail-
ability and a half-life of 2–3 h (rofecoxib) and 1 h (etori-
coxib), celecoxib and valdecoxib (or its prodrug parecox-
ib) are sulfonamides  [6, 43, 44] . Except for valdecoxib, 
their oral bioavailability is lower than that of the sulfonyls 
(parecoxib is only available as an intravenous drug), but 
their half-lives are similar, being 2–4 h  [6, 43, 44] . Lumi-
racoxib, the most recently developed COX-2 inhibitor, 
has a phenyl acetic acid structure, but also has suffi cient 
oral bioavailability and a half-life of 2–3 h. However, it 
differs from the previous drugs in terms of selectivity for 
COX-2 because lumiracoxib is the most selective COX-2 
inhibitor known so far  [6, 44, 45] . This selectivity of a 
certain COX-2 inhibitor could be of importance in terms 
of cardiovascular side effects, as it theoretically should 
exert direct effects on the balance between TxA 2  and 
PGI 2 . Before clinical application, the selectivity of a drug 
targeting cyclooxygenases is usually tested by a human 
whole blood assay. Based on such investigations, rofe-
coxib and valdecoxib have been found to have compa-
rable selectivities at a COX-1/COX-2 ratio of about 270, 
which is slightly exceeded by that of etoricoxib, which 
exhibits a value of about 340. Celecoxib greatly differs 
from them because its selectivity for COX-2 is rather low 
when compared to the other coxibs, its COX-1/COX-2 
ratio is only about 30 (selectivity data differ markedly ac-
cording to source, however, the proportions of differ - 
ences between several coxibs are similar throughout most 
studies; numbers presented here are taken from a review 
by FitzGerald  [6] ). As these data do not necessarily rep-
resent the in vivo behavior of a drug, studies corroborat-
ing in vivo selectivity of COX-2 inhibitors by showing 
their omission of an infl uence on TxA 2  formation have 
been undertaken and have proved the selectivity of rofe-
coxib  [46] , valdecoxib  [47, 48] , parecoxib, etoricoxib and 
lumiracoxib  [49] . Of note, according to in vitro data, ce-
lecoxib is only a little more selective than diclofenac, 
which also has a ratio in favor of COX-2 of about 20  [6, 
14] . This rather low selectivity in comparison to other 
coxibs may explain the missing advantage of celecoxib in 
terms of gastrointestinal toxicity, when compared to di-
clofenac or ibuprofen (which only has a COX-1/COX-2 
ratio of about 0.5), and may also be of importance for the 
cardiovascular side effects that can be expected from a 
coxib. Except for rofecoxib, which is reduced cytosoli-
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cally, all known coxibs are metabolized through oxidation 
by cytochrome P 450  enzymes, of which either the 3A4 
isoform (celecoxib, valdecoxib/parecoxib or etoricoxib) 
or the 2C9 isoform (celecoxib, valdecoxib/parecoxib or 
lumiracoxib) do the job  [6, 43, 45, 50] . Metabolism by 
cytochromes may be of importance for specifi c side ef-
fects of the drugs for two reasons. First, drug-drug inter-
actions with other substances are often due to metabolism 
by the same cytochrome P 450  isoform  [50] . Such interac-
tions can either lead to an increased plasma level of a 
drug, when there is competition for metabolism by the 
same CYP isoform with another drug, or to an increased 
metabolism through induction of the CYP enzyme, which 
can cause decreased levels of a drug or even increase the 
effi ciency of a drug if the drug has to be metabolized to 
be active. A prominent example for the latter is clopido-
grel, which is a prodrug metabolized by CYP3A4 to its 
active form. Second, CYP2C9, especially in the microcir-
culation, is the source for an important autacoid, the en-
dothelium-derived hyperpolarizing factor  [51, 52] . 
 Studies investigating the effi ciency of the newer coxibs 
valdecoxib/parecoxib, etoricoxib and lumiracoxib have 
all been published and have repeatedly shown the supe-
riority of these drugs in comparison to NSAID in terms 
of gastrointestinal toxicity  [53–55] . 
 Infl uence of Selective COX-2 Inhibitors on 
Vascular Formation of Prostanoids 
 The actual effect of a coxib on prostanoid availability 
is of high importance for the expected effi ciency and the 
probable side effects of these drugs. In terms of vascular 
function and thrombosis, the most relevant prostanoids 
of interest are PGI 2  and TxA 2   [5] . Measurement of cyclo-
oxygenase-derived prostanoids, which are short-lived 
and cannot be assessed directly, is usually performed 
through assessment of its metabolites in urine or serum. 
Thus, serum levels of 6-keto-PGF 1   or urine levels of 2,3-
dinor 6-keto-PGF 1   are usually measured as an index of 
PGI 2  production, whereas TxA 2  levels are represented by 
urinary 11-dehydro TxB 2  or serum levels of TxB 2 . For 
matters of simplicity, PGI 2  metabolites will be referred 
to as PGI-M, whereas TxA 2  metabolites will be referred 
to as Tx-M in the following. 
 In an early study comparing rofecoxib with the NSAID 
indomethacin in elderly adults, it was fi rst observed that 
COX-2 has a major role in systemic PGI 2  production, 
because rofecoxib (50 mg/day) was as effective in reduc-
ing PGI-M as was indomethacin (50 mg/bid, both grossly 
halved PGI-M levels after 13 days of treatment), but in 
contrast to indomethacin, Tx-M left levels unchanged 
 [46] . In a similar study in healthy volunteers, celecoxib, 
after 4–6 h of dosing only, reduced PGI-M by about 80% 
(800 mg) or 70% (400 mg), whereas ibuprofen (800 mg) 
only reached a 66% reduction at that time point  [56] . In-
terestingly, and in accordance with its rather low selectiv-
ity for COX-2, one dose of celecoxib (800 mg, assessed at 
4 h) also caused a statistically signifi cant reduction of 
about 28% for one of two Tx-M that were measured (ibu-
profen caused a maximum reduction of more than 95% 
of Tx-M)  [56] . Reduction of PGI-M by other selective 
inhibitors of COX-2 has repeatedly been observed in an-
imal or human models  [57–60] . 
 Whereas these data were all obtained in healthy sub-
jects, they do not allow drawing conclusions about the 
infl uence of cyclooxygenase inhibitors on prostanoid for-
mation during infl ammation or agonist stimulation, 
where the main prostanoid produced by one cyclooxygen-
ase isoform may not be the same as under basal condi-
tions  [32,  61] . The selective inhibitor of COX-2 SC58236 
(Pharmacia) blunted the production of PGE 2  and PGI-M 
in the renal medulla of angiotensin-II-stimulated mice 
 [61] . In a human study comparing the effect of endotoxin 
(lipopolysaccharide, LPS) on prostanoid metabolism un-
der control conditions, inhibition of COX-1 (low-dose 
aspirin for 10 days before LPS), non-specifi c COX inhibi-
tion (ibuprofen, 800 mg once prior to LPS), or selective 
inhibition of COX-2 (celecoxib, 800 mg prior to LPS), 
both ibuprofen and celecoxib, but not low-dose aspirin, 
were able to reduce the increase in body temperature 
caused by LPS. Low-dose aspirin completely reduced 
platelet-dependent TxA 2  formation, and thus prevented 
the major part of systemic Tx-M (which also meant that 
a minor part of systemic TxA 2  was produced in other tis-
sues than platelets), whereas ibuprofen completely blunt-
ed Tx-M from any source. Moreover, both ibuprofen and 
celecoxib drastically reduced levels of PGI-M, whereas 
low-dose aspirin only had little effect  [62] . This showed 
that COX-2 also signifi cantly contributed to PGI 2  pro-
duction during endotoxinemia. In atherosclerotic pa-
tients, the selective COX-2 inhibitor nimesulide (a rather 
selective sulfonanilide distributed in some European 
countries) reduced PGI-M by about 46%  [60] . Similar 
reductions in PGI-M were observed for different selective 
inhibitors of COX-2 in hypertension  [63] , upon stimula-
tion with norepinephrine  [64] , under hypoxic conditions 
 [65] or in LDL-receptor knockout mice  [66] , whereas Tx-
M levels remained unchanged  [63, 66] or were even ele-
vated  [65] . There is evidence that the vascular expression 
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of COX-2 may even be upregulated with age or in ad-
vanced atherosclerosis. The effect of COX-2 inhibition 
on both TxA 2  and PGI 2  release was more pronounced in 
aortic rings from aged rats compared to younger animals 
 [67] . Similar observations, such as a benefi cial effect of 
COX-2 inhibition on fl ow-mediated dilation in male pa-
tients with atherosclerosis, have stimulated a discussion 
about potential benefi cial effects of COX-2 inhibition in 
the treatment of cardiovascular disease  [68, 69] . How-
ever, other studies in human  [70] or animal models  [71] 
of endothelial function, atherosclerosis or infl ammation 
failed to observe such benefi cial effects. 
 In addition to factors like age, the stage of atheroscle-
rotic diseases or the extent of preexisting endothelial 
function, gender and the interaction of prostanoids with 
the production of other autacoids contribute to the role 
of COX-2-dependent prostanoid formation in vivo. In 
ovariectomized mice defi cient in endothelial NO syn-
thase, estrogen treatment increased prostanoid-depen-
dent vasodilatation, but failed to do so in the presence of 
functional NO production  [72] . Estrogen has recently 
been shown to upregulate COX-2-dependent PGI 2  pro-
duction in female mice  [73] concomitant with decreased 
oxidant stress and platelet activation. Another study ob-
served increased renal PGE 2  and TxA 2  production asso-
ciated with greater medullary COX-2 expression in fe-
male spontaneously hypertensive rats  [74] . In this study, 
however, orchidectomy led to an increase in PGE 2  release 
in males, indicating that male sex hormones might also 
contribute to gender-dependent differences in prostanoid 
production  [74] . 
 Altogether, the data at hand so far suggest that in con-
trast to NSAID or low-dose aspirin, selective inhibitors 
of COX-2 usually have no effect on systemic TxA 2  levels, 
but rather reduce PGI 2  release in healthy individuals. Al-
though infl ammatory diseases or disorders of the cardio-
vascular system, e.g. hypertension, may have altered cy-
clooxygenase isoform expression patterns or altered pro-
duction of cyclooxygenase-dependent prostanoids, the 
effect of coxibs on PGI 2  levels seems to prevail. 
 Risk of Arterial Thrombosis 
 Given that PGI 2  and TxA 2  are the two most important 
prostanoids with respect to platelet activation, it is easy 
to perceive that any drug that selectively reduces plasma 
levels of a physiological antiplatelet substance like PGI 2 , 
without altering levels of the corresponding platelet acti-
vator, TxA 2 , theoretically has an intrinsic likeliness of 
increasing the activity of circulating platelets. However, 
although selective COX-2 inhibitors have been suspected 
to increase the risk for intravital platelet activation and 
subsequent thrombosis due to clinical fi ndings or theo-
retical considerations ever since the VIGOR trial, initial 
experimental approaches aimed at proving this hypoth-
esis did not succeed in fi nding indications for an enhanced 
risk of thrombosis, which may have been due to the low 
sensitivity of the assays used (platelet deposition in his-
tological samples)  [59] . First evidence for an enhanced 
thrombotic risk under elective inhibition of COX-2 was 
gathered by Hennan et al.  [75] in dogs: in this study, high-
dose aspirin had no effect on coronary artery thrombotic 
occlusion unless it was withdrawn and a recovery time 
for the endothelium to resynthesize cyclooxygenase was 
allowed for. After the endothelium had recovered cyclo-
oxygenase (but not platelets because of the irreversible 
binding of aspirin), there was an increased time to throm-
botic occlusion, but this antithrombotic effect was pre-
vented by the administration of celecoxib during recov-
ery. Very recently, two experimental studies, using either 
highly sensitive methods for assessing enhanced throm-
bogenicity or more adequate disease models, clearly 
proved that there is a thrombotic risk under selective in-
hibition of COX-2 in vivo. The fi rst of these studies, 
which was published just few days before the withdrawal 
of Vioxx from global markets, used a highly sensitive in 
vivo microcirculatory model. It revealed that selective 
inhibition of COX-2 enhanced platelet activation, lead-
ing to increased platelet rolling at the intact arteriolar 
wall. Moreover, fi rm platelet adhesion was increased and 
ultimately a markedly reduced time to thrombotic occlu-
sion upon vessel wall damage resulted  [57] . The second 
study – appearing shortly thereafter – showed that during 
hypoxia in the pulmonary circulation of rats, there was 
enhanced platelet activation under selective inhibition of 
COX-2  [65] . Notably, in all these studies, selective in-
hibitors of COX-2 have not been reported to cause spon-
taneous thrombosis  [57, 59, 65] . Nevertheless, these stud-
ies could prove what already was theoretically plausible: 
that selective COX-2 inhibitors enhance platelet activa-
tion and thus are able to trigger the onset of thrombotic 
events. 
 Although the VIGOR study had not been designed to 
investigate side effects of rofecoxib, it brought about the 
alarming result of a nearly 5-fold increased risk of myo-
cardial infarction in those patients that received rofecox-
ib; they would have needed to take low-dose aspirin for 
secondary cardiovascular prophylaxis, but could not do 
so because of the study design  [40] . This fi nding has 
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prompted vigorous discussion among scientists as to 
whether this was a mechanistically induced ‘class’ effect 
of all selective COX-2 inhibitors, or whether it was an 
intrinsic problem of rofecoxib. Alternatively, it was dis-
cussed whether the increase in myocardial infarctions in 
the rofecoxib group was due to an intrinsic antiplate-
let – and thus cardioprotective – property of naproxen, 
which was used as the NSAID that rofecoxib was com-
pared with. The authors of the VIGOR study related this 
difference to such a potential antiplatelet property of 
naproxen. However, future studies failed to convincingly 
prove its cardioprotective properties  [16, 76, 77] . Naprox-
en – being an NSAID – turned indeed out to be able to 
inhibit platelet COX-1-dependent TxA 2  production al-
most as effectively as low-dose aspirin, which is why it 
can prevent platelet aggregation in  ex vivo  assays (where 
there is no endothelium to supply PGI 2 ), but also inhib-
ited systemic PGI 2  production in vivo, which is a critical 
difference when comparing it to low-dose aspirin  [16] . In 
our opinion, naproxen is unlikely to have exerted an as-
pirin-like coronary-protective effect in the VIGOR study. 
In addition, it has recently become clearer that rofecoxib 
may indeed have intrinsic atherothrombotic features. A 
correlation between myocardial infarction and rofecoxib 
was also found in the recent APPROVe study, which was 
stopped because there was an increased risk of athero-
thrombotic complications after 18 months of rofecoxib 
intake  [78] . Large meta-analyses of randomized trials 
yielded similar results ( table 1 )  [79, 80] . Although these 
circumstances had prompted the withdrawal of rofecoxib 
from global markets, many questions remained. Besides 
ethical questions relating to market introduction of a new 
drug, to date the most important question for clinicians 
is whether all the other coxibs also exert a prothrombotic 
effect and if so, whether only long-term use or short-term 
intake of a coxib bears the risk of myocardial infarc-
tion? 
 There are more data at hand now to shed light on the 
question of a potential class effect: the manufacturer of 
 celecoxib has issued a warning of potential cardiovascular 
atherothrombotic side effects in December 2004 due to 
preliminary results from the Adenoma Prevention with 
Celecoxib Trial  [81] , which gives evidence for dose- and 
time-of-intake-related increases in cardiovascular events 
due to celecoxib  [82] . Before this, there had been one in-
cidental report about thrombotic events in 4 patients with 
connective tissue disease who had taken celecoxib  [15] , 
but neither the large randomized CLASS study nor any 
clinical trial had shown an enhanced risk of myocardial 
infarction following celecoxib treatment, and some sur-
veys that observed an enhanced risk for rofecoxib failed 
to do so in patients taking celecoxib ( table 1 )  [80, 83] . This 
lack of prior evidence may have been due to the fact that 
the CLASS study was conducted in a cohort of patients 
who – in contrast to the study population in VIGOR 
(rheumatoid arthritis) – did not have an increased risk 
for cardiovascular disease (mainly osteoarthritis patients) 
 [84] . However, the lower COX-2 selectivity of celecoxib, 
which also partly reduces Tx-M levels in vivo  [56] , gives 
reason to question whether celecoxib will really cause an 
 Table 1. List of studies showing an increased risk of atherothrombotic events during intake of selective inhibitors 
of COX-2 
Coxib Study or authors Patients Publication
date
Reference No.
Rofecoxib VIGOR 8,076 2000 40
APPROVe 2,586 2004 78
Kaiser-Permanente   1.4 ! 106 2004 www.fda.gov/cder/drug/infopage/
vioxx/vioxxgraham.pdf
Juni et al. 20,742 2004 79
Solomon et al. 54,475 2004 80
Celecoxib APC 2,035 2004 82
Parecoxib/
valdecoxib
McSPI (CABG)
Nussmeier et al.
00,462
01,671
2003
2005
85
86
Of note, in some of the studies shown here, an increased risk for rofecoxib but not for celecoxib was observed. 
One analysis even found an increased risk during intake of NSAID (Kaiser-Permanente). CABG = Coronary ar-
tery bypass grafting; APC = Adenoma Prevention with Celecoxib Trial; APPROVe = Adenomatous Poly Preven-
tion on Vioxx Trial.
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enhanced atherothrombotic risk. In support of a theory 
assigning higher risks of adverse cardiovascular events to 
those coxibs that are more specifi c are recent data from a 
study of parecoxib/valdecoxib in patients undergoing cor-
onary artery bypass grafting  [85] . The most recently pub-
lished study by Nussmeier et al.  [86] confi rmed these ini-
tial observations in a larger population. However, a ret-
rospective meta-analysis screening nearly 8,000 patients 
who had received valdecoxib at different dosing regimes 
during clinical studies for osteoarthritis or rheumatoid 
arthritis found no increased incidence of myocardial in-
farction when comparing valdecoxib with nonselective 
NSAID  [87] . The recent TARGET trial comparing lumi-
racoxib ,  which is the most selective COX-2 inhibitor so 
far, with naproxen and ibuprofen also found no correla-
tion between the incidence of myocardial infarction and 
treatment with lumiracoxib  [88] . To the best of our knowl-
edge, no data in support of such as risk for lumiracoxib 
or etoricoxib are at hand up to date, but several smaller 
studies did not fi nd an increased risk of myocardial in-
farction during their use  [55, 89] .  Table 1 summarizes the 
clinical evidence for atherothrombotic events associated 
with different coxibs. 
 Although theoretically the risk of atherothrombotic 
events should increase with the selectivity of the drug for 
COX-2, this property of a coxib alone does not suffi ce for 
the event to occur with a statistically signifi cant likeliness. 
Other factors, such as the dose of the drug that is taken 
and the time of intake, will naturally contribute to the 
likeliness of an event to occur. In addition, there is good 
evidence that the prothrombotic risk is most pronounced 
in patients who are already at an increased risk of athero-
thrombotic events due to their underlying disease. 
 Other Cardiovascular Effects 
 Because of their likeliness to selectively inhibit endo-
thelial PGI 2  synthesis and thus unbalance the equilibri-
um between vascular TxA 2  and PGI 2  in favor of the va-
soconstrictor TxA 2 , several other cardiovascular or re-
lated effects, e.g. disturbance of vision (due to potentially 
altered blood supply)  [90] , may theoretically occur. Like 
NSAID, coxibs are likely to moderately elevate systemic 
blood pressure  [91] , which is probably due not only to 
detrimental effects on the endothelial function but also 
to nephrotoxicity  [92] . However, the effect of selective 
inhibition of COX-2 on endothelial function may also be 
benefi cial, as repeatedly shown in patients with ischemic 
heart disease  [68, 69] . These fi ndings are in accordance 
with a proinfl ammatory role of COX-2-derived PGI 2  in 
atherosclerosis development  [66] and have formed a basis 
for discussing a potential use of selective COX-2 inhibi-
tors in patients with coronary heart disease  [93] . Similar 
to myocardial infarction, further atherothrombotic ef-
fects such as stroke or pulmonary embolism are likely to 
occur at increased rate, and this has already been ob-
served in some of the clinical studies  [78, 86] . The
APPROVe trial also reported differences in groups in 
events like congestive heart failure, pulmonary edema or 
cardiac failure  [78] . However, the likeliness for an ad-
verse event to occur may differ markedly according to the 
underlying disease, as prostacyclin synthesis is also known 
to interact with nitric oxide synthesis in the vasculature, 
with diverging net outcomes for thrombosis, endothelial 
function or atherogenesis. 
 Outlook 
 According to the data available on selective COX-2 
inhibitors and their known effects on vascular pathophys-
iology and the balance between PGI 2  and TxA 2 , it is high-
ly likely that the risk for thrombotic events is a class effect 
inherent in coxibs. This effect is likely to occur preferen-
tially in patients who already have an increased risk to 
experience atherothrombosis, because selective inhibi-
tors of COX-2 do not cause thrombosis themselves, but 
rather support its onset. For some time, partly because of 
a lack of suffi cient data, the risk had only been suspected 
for rofecoxib, but newer data suggest that it may also com-
plicate the use of other coxibs. In addition to the physi-
ological mechanisms leading to the described vascular 
imbalance between PGI 2  and TxA 2 , other vascular phe-
nomena, such as the recently described upregulation of 
thrombomodulin by COX-2-formed prostanoids  [94] or 
the diverse interactions of endothelial autacoids, e.g. NO, 
with prostanoid production  [95] , may also contribute to 
the enhanced risk of thrombotic complications. Due to 
pharmacokinetic and chemical differences in the various 
substances available, some of these compounds may not 
bear this risk at all. Thus, a critical evaluation as to the 
extent of this risk should be performed for each of the 
COX-2 inhibitors separately. Such evaluation should 
compare the extent of in vivo inhibition of PGI 2  synthe-
sis with TxA 2 , as the balance between these prostanoids 
is the key to an effect of any cyclooxygenase inhibition on 
thrombosis and can easily be assessed in humans. More-
over, the pathophysiology of the underlying diseases of 
individual patients destined to be treated with coxibs 
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must be considered when using these drugs. Whereas 
some patient groups may benefi t from their advantages, 
others are more likely to be harmed by detrimental ef-
fects, as nicely demonstrated in a statistical post hoc anal-
ysis of the VIGOR population  [96] . It should be borne in 
mind that selective COX-2 inhibitors are well tolerated 
by most patients, that they offer reliable relief from pain 
and infl ammation, and that they are highly appreciated 
by those who use them. All health professionals should be 
aware of the fact that there is a risk. However, they should 
also be aware of its likely limitations and thus be able to 
individually decide on patients who are apt to receive se-
lective COX-2 inhibitors. If the cardiovascular risk of a 
certain patient is in doubt, they should be prescribed cau-
tiously. In the present modern medicine, physicians face 
increasing numbers of patients with complex, multiple 
disease. It is not unlikely that a patient may require effec-
tive anti-infl ammatory treatment but also has a high risk 
for both gastrointestinal bleeding and cardiovascular 
thrombosis. In these patients, physicians may want to 
consider the concurrent use of selective COX-2 inhibitors 
with antiplatelet agents other than low-dose aspirin, who 
do not have gastrointestinal toxic side effects, and corre-
sponding studies may be warranted for special patient 
subsets. 
 
 
 References 
 1 Topol EJ: Failing the public health – rofecoxib, 
Merck, and the FDA. N Engl J Med 2004;  351: 
 1707–1709. 
 2 Josefson D: FDA warns Merck over its promo-
tion of rofecoxib. BMJ 2001;  323:  767. 
 3 Walter MF, Jacob RF, Day CA, Dahlborg R, 
Weng Y, Mason RP: Sulfone COX-2 inhibitors 
increase susceptibility of human LDL and 
plasma to oxidative modifi cation: comparison 
to sulfonamide COX-2 inhibitors and NSAIDs. 
Atherosclerosis 2004;  177:  235–243. 
 4 Warner TD, Mitchell JA: Cyclooxygenases: 
new forms, new inhibitors, and lessons from 
the clinic. FASEB J 2004;  18:  790–804. 
 5 Davidge ST: Prostaglandin H synthase and 
vascular function. Circ Res 2001;  89:  650–
660. 
 6 FitzGerald GA: COX-2 and beyond: ap-
proaches to prostaglandin inhibition in human 
disease. Nat Rev Drug Discov 2003;  2:  879–
890. 
 7 Smith WL, DeWitt DL, Garavito RM: Cyclo-
oxygenases: structural, cellular, and molecular 
biology. Annu Rev Biochem 2000;  69:  145–
182. 
 8 Chandrasekharan NV, Dai H, Roos KL, et al: 
COX-3, a cyclooxygenase-1 variant inhibited 
by acetaminophen and other analgesic/anti-
pyretic drugs: cloning, structure, and expres-
sion. Proc Natl Acad Sci USA 2002;  99:  13926–
13931. 
 9 Schwab JM, Schluesener HJ, Laufer S: COX-3: 
just another COX or the solitary elusive target 
of paracetamol? Lancet 2003;  361:  981–982. 
 10 Helliwell RJ, Adams LF, Mitchell MD: Pros-
taglandin synthases: recent developments and 
a novel hypothesis. Prostaglandins Leukot Es-
sent Fatty Acids 2004;  70:  101–113. 
 11 FitzGerald GA: Mechanisms of platelet activa-
tion: thromboxane A2 as an amplifying signal 
for other agonists. Am J Cardiol 1991;  68:  11B–
15B. 
 12 Armstrong RA: Platelet prostanoid receptors. 
Pharmacol Ther 1996;  72:  171–191. 
 13 Patrono C, Coller B, Dalen JE, et al: Platelet-
active drugs: the relationships among dose, ef-
fectiveness, and side effects. Chest 2001;  119: 
 39S–63S. 
 14 Patrono C, Patrignani P, Garcia Rodriguez 
LA: Cyclooxygenase-selective inhibition of 
prostanoid formation: transducing biochemi-
cal selectivity into clinical read-outs. J Clin In-
vest 2001;  108:  7–13. 
 15 Crofford LJ, Oates JC, McCune WJ, et al: 
Thrombosis in patients with connective tissue 
diseases treated with specifi c cyclooxygenase 2 
inhibitors. A report of four cases. Arthritis 
Rheum 2000;  43:  1891–1896. 
 16 Capone ML, Tacconelli S, Sciulli MG, et al: 
Clinical pharmacology of platelet, monocyte, 
and vascular cyclooxygenase inhibition by 
naproxen and low-dose aspirin in healthy sub-
jects. Circulation 2004;  109:  1468–1471. 
 17 Lipsky PE: Role of cyclooxygenase-1 and -2 in 
health and disease. Am J Orthop 1999;  28:  8–
12. 
 18 Buttar NS, Wang KK: The ‘aspirin’ of the new 
millennium: cyclooxygenase-2 inhibitors. 
Mayo Clin Proc 2000;  75:  1027–1038. 
 19 Hinz B, Brune K, Pahl A: Cyclooxygenase-2 
expression in lipopolysaccharide-stimulated 
human monocytes is modulated by cyclic 
AMP, prostaglandin E(2), and nonsteroidal 
anti-infl ammatory drugs. Biochem Biophys 
Res Commun 2000;  278:  790–796. 
 20 Hinz B, Brune K: Cyclooxygenase-2 – 10 years 
later. J Pharmacol Exp Ther 2002;  300:  367–
375. 
 21 Zimmermann KC, Sarbia M, Schror K, Weber 
AA: Constitutive cyclooxygenase-2 expression 
in healthy human and rabbit gastric mucosa. 
Mol Pharmacol 1998;  54:  536–540. 
 22 Iseki S: Immunocytochemical localization of 
cyclooxygenase-1 and cyclooxygenase-2 in the 
rat stomach. Histochem J 1995;  27:  323–328. 
 23 Nantel F, Meadows E, Denis D, Connolly B, 
Metters KM, Giaid A: Immunolocalization of 
cyclooxygenase-2 in the macula densa of hu-
man elderly. FEBS Lett 1999;  457:  475–477. 
 24 Chakraborty I, Das SK, Wang J, Dey SK: De-
velopmental expression of the cyclo-oxygen-
ase-1 and cyclo-oxygenase-2 genes in the peri-
implantation mouse uterus and their 
differential regulation by the blastocyst and 
ovarian steroids. J Mol Endocrinol 1996;  16: 
 107–122. 
 25 Slater DM, Dennes WJ, Campa JS, Poston L, 
Bennett PR: Expression of cyclo-oxygenase 
types-1 and -2 in human myometrium through-
out pregnancy. Mol Hum Reprod 1999;  5:  880–
884. 
 26 Slater D, Dennes W, Sawdy R, Allport V, Ben-
nett P: Expression of cyclo-oxygenase types-1 
and -2 in human fetal membranes throughout 
pregnancy. J Mol Endocrinol 1999;  22:  125–
130. 
 27 Damm J, Rau T, Maihofner C, Pahl A, Brune 
K: Constitutive expression and localization of 
COX-1 and COX-2 in rabbit iris and ciliary 
body. Exp Eye Res 2001;  72:  611–621. 
 28 Tegeder I, Neupert W, Guhring H, Geisslinger 
G: Effects of selective and unselective cyclo-
oxygenase inhibitors on prostanoid release 
from various rat organs. J Pharmacol Exp Ther 
2000;  292:  1161–1168. 
 29 Parente L, Perretti M: Advances in the patho-
physiology of constitutive and inducible cyclo-
oxygenases: two enzymes in the spotlight. Bio-
chem Pharmacol 2003;  65:  153–159. 
 30 Murphy JF, Steele C, Belton O, Fitzgerald DJ: 
Induction of cyclooxygenase-1 and -2 modu-
lates angiogenic responses to engagement of 
alphavbeta3. Br J Haematol 2003;  121:  157–
164. 
 COX-2 Inhibitors and Myocardial 
Infarction 
 J Vasc Res 2005;42:312–324 323
 31 Liou JY, Shyue SK, Tsai MJ, Chung CL, Chu 
KY, Wu KK: Colocalization of prostacyclin 
synthase with prostaglandin H synthase-1 
(PGHS-1) but not phorbol ester-induced 
PGHS-2 in cultured endothelial cells. J Biol 
Chem 2000;  275:  15314–15320. 
 32 Camacho M, Lopez-Belmonte J, Vila L: Rate 
of vasoconstrictor prostanoids released by en-
dothelial cells depends on cyclooxygenase-2 ex-
pression and prostaglandin I synthase activity. 
Circ Res 1998;  83:  353–365. 
 33 Wright DH, Abran D, Bhattacharya M, et al: 
Prostanoid receptors: ontogeny and implica-
tions in vascular physiology. Am J Physiol 
Regul Integr Comp Physiol 2001;  281:R1343–
R1360. 
 34 Morrison BW, Christensen S, Yuan W, Brown 
J, Amlani S, Seidenberg B: Analgesic effi cacy 
of the cyclooxygenase-2-specifi c inhibitor rofe-
coxib in post-dental surgery pain: a random-
ized, controlled trial. Clin Ther 1999;  21:  943–
953. 
 35 Reicin A, Brown J, Jove M, et al: Effi cacy of 
single-dose and multidose rofecoxib in the 
treatment of post-orthopedic surgery pain. Am 
J Orthop 2001;  30:  40–48. 
 36 Cannon GW, Caldwell JR, Holt P, et al: Rofe-
coxib, a specifi c inhibitor of cyclooxygenase 2, 
with clinical effi cacy comparable with that of 
diclofenac sodium: results of a one-year, ran-
domized, clinical trial in patients with osteoar-
thritis of the knee and hip. Rofecoxib Phase III 
Protocol 035 Study Group. Arthritis Rheum 
2000;  43:  978–987. 
 37 Day R, Morrison B, Luza A, et al: A random-
ized trial of the effi cacy and tolerability of the 
COX-2 inhibitor rofecoxib vs ibuprofen in pa-
tients with osteoarthritis. Rofecoxib/Ibuprofen 
Comparator Study Group. Arch Intern Med 
2000;  160:  1781–1787. 
 38 Simon LS, Lanza FL, Lipsky PE, et al: Pre-
liminary study of the safety and effi cacy of SC-
58635, a novel cyclooxygenase 2 inhibitor: ef-
fi cacy and safety in two placebo-controlled 
trials in osteoarthritis and rheumatoid arthri-
tis, and studies of gastrointestinal and platelet 
effects. Arthritis Rheum 1998;  41:  1591–1602. 
 39 Laine L, Harper S, Simon T, et al: A random-
ized trial comparing the effect of rofecoxib, a 
cyclooxygenase 2-specifi c inhibitor, with that 
of ibuprofen on the gastroduodenal mucosa of 
patients with osteoarthritis. Rofecoxib Osteo-
arthritis Endoscopy Study Group. Gastroen-
terology 1999;  117:  776–783. 
 40 Bombardier C, Laine L, Reicin A, et al: Com-
parison of upper gastrointestinal toxicity of ro-
fecoxib and naproxen in patients with rheuma-
toid arthritis. VIGOR Study Group. N Engl J 
Med 2000;  343:  1520–1528. 
 41 Silverstein FE, Faich G, Goldstein JL, et al: 
Gastrointestinal toxicity with celecoxib vs 
nonsteroidal anti-infl ammatory drugs for os-
teoarthritis and rheumatoid arthritis: the 
CLASS study: a randomized controlled trial. 
Celecoxib Long-Term Arthritis Safety Study. 
JAMA 2000;  284:  1247–1255. 
 42 FitzGerald GA: Parsing an enigma: the phar-
macodynamics of aspirin resistance. Lancet 
2003;  361:  542–544. 
 43 Riendeau D, Percival MD, Brideau C, et al: 
Etoricoxib (MK-0663): preclinical profi le and 
comparison with other agents that selectively 
inhibit cyclooxygenase-2. J Pharmacol Exp 
Ther 2001;  296:  558–566. 
 44 Brune K, Hinz B: Selective cyclooxygenase-2 
inhibitors: similarities and differences. Scand 
J Rheumatol 2004;  33:  1–6. 
 45 Lyseng-Williamson KA, Curran MP: Lumira-
coxib. Drugs 2004;  64:  2237–2246. 
 46 Catella-Lawson F, McAdam B, Morrison BW, 
et al: Effects of specifi c inhibition of cyclooxy-
genase-2 on sodium balance, hemodynamics, 
and vasoactive eicosanoids. J Pharmacol Exp 
Ther 1999;  289:  735–741. 
 47 Leese PT, Recker DP, Kent JD: The COX-2 
selective inhibitor, valdecoxib, does not impair 
platelet function in the elderly: results of a ran-
domized controlled trial. J Clin Pharmacol 
2003;  43:  504–513. 
 48 Leese PT, Talwalker S, Kent JD, Recker DP: 
Valdecoxib does not impair platelet function. 
Am J Emerg Med 2002;  20:  275–281. 
 49 Stichtenoth DO: The second generation of 
COX-2 inhibitors: clinical pharmacological 
point of view. Mini Rev Med Chem 2004;  4: 
 617–624. 
 50 Garnett WR: Clinical implications of drug in-
teractions with coxibs. Pharmacotherapy 2001; 
 21:  1223–1232. 
 51 Krotz F, Riexinger T, Buerkle MA, et al: Mem-
brane potential-dependent inhibition of plate-
let adhesion to endothelial cells by epoxyeico-
satrienoic acids. Arterioscler Thromb Vasc 
Biol 2004;  24:  595–600. 
 52 Hoepfl  B, Rodenwaldt B, Pohl U, De Wit C: 
EDHF, but not NO or prostaglandins, is criti-
cal to evoke a conducted dilation upon ACh in 
hamster arterioles. Am J Physiol Heart Circ 
Physiol 2002;  283:H996–H1004. 
 53 Schnitzer TJ, Burmester GR, Mysler E, et al: 
Comparison of lumiracoxib with naproxen 
and ibuprofen in the Therapeutic Arthritis Re-
search and Gastrointestinal Event Trial (TAR-
GET), reduction in ulcer complications: ran-
domised controlled trial. Lancet 2004;  364: 
 665–674. 
 54 Sikes DH, Agrawal NM, Zhao WW, Kent JD, 
Recker DP, Verburg KM: Incidence of gastro-
duodenal ulcers associated with valdecoxib 
compared with that of ibuprofen and diclofe-
nac in patients with osteoarthritis. Eur J Gas-
troenterol Hepatol 2002;  14:  1101–1111. 
 55 Hunt RH, Harper S, Watson DJ, et al: The 
gastrointestinal safety of the COX-2 selective 
inhibitor etoricoxib assessed by both endosco-
py and analysis of upper gastrointestinal 
events. Am J Gastroenterol 2003;  98:  1725–
1733. 
 56 McAdam BF, Catella-Lawson F, Mardini IA, 
Kapoor S, Lawson JA, FitzGerald GA: System-
ic biosynthesis of prostacyclin by cyclooxygen-
ase (COX)-2: the human pharmacology of a 
selective inhibitor of COX-2. Proc Natl Acad 
Sci USA 1999;  96:  272–277. 
 57 Buerkle MA, Lehrer S, Sohn HY, Conzen P, 
Pohl U, Krotz F: Selective inhibition of cyclo-
oxygenase-2 enhances platelet adhesion in 
hamster arterioles in vivo. Circulation 2004; 
 110:  2053–2059. 
 58 Kearney D, Byrne A, Crean P, Cox D, Fitzger-
ald DJ: Optimal suppression of thromboxane 
A 2  formation by aspirin during percutaneous 
transluminal coronary angioplasty: no addi-
tional effect of a selective cyclooxygenase-2 in-
hibitor. J Am Coll Cardiol 2004;  43:  526–531. 
 59 Belton OA, Duffy A, Toomey S, Fitzgerald DJ: 
Cyclooxygenase isoforms and platelet vessel 
wall interactions in the apolipoprotein E 
knockout mouse model of atherosclerosis. Cir-
culation 2003;  108:  3017–3023. 
 60 Belton O, Byrne D, Kearney D, Leahy A, 
Fitzgerald DJ: Cyclooxygenase-1 and -2-de-
pendent prostacyclin formation in patients 
with atherosclerosis. Circulation 2000;  102: 
 840–845. 
 61 Qi Z, Hao CM, Langenbach RI, et al: Opposite 
effects of cyclooxygenase-1 and -2 activity on 
the pressor response to angiotensin II. J Clin 
Invest 2002;  110:  61–69. 
 62 McAdam BF, Mardini IA, Habib A, et al: Ef-
fect of regulated expression of human cyclo-
oxygenase isoforms on eicosanoid and isoei-
cosanoid production in infl ammation. J Clin 
Invest 2000;  105:  1473–1482. 
 63 Widlansky ME, Price DT, Gokce N, et al: 
Short- and long-term COX-2 inhibition re-
verses endothelial dysfunction in patients with 
hypertension. Hypertension 2003;  42:  310–
315. 
 64 Llinas MT, Lopez R, Rodriguez F, Roig F, 
Salazar FJ: Role of COX-2-derived metabo-
lites in regulation of the renal hemodynamic 
response to norepinephrine. Am J Physiol Re-
nal Physiol 2001;  281:F975–F982. 
 65 Pidgeon GP, Tamosiuniene R, Chen G, et al: 
Intravascular thrombosis after hypoxia-in-
duced pulmonary hypertension: Regulation by 
cyclooxygenase-2. Circulation 2004;  110: 
 2701–2707. 
 66 Burleigh ME, Babaev VR, Oates JA, et al: Cy-
clooxygenase-2 promotes early atherosclerotic 
lesion formation in LDL receptor-defi cient 
mice. Circulation 2002;  105:  1816–1823. 
 67 Heymes C, Habib A, Yang D, et al: Cyclo-oxy-
genase-1 and -2 contribution to endothelial 
dysfunction in ageing. Br J Pharmacol 2000; 
 131:  804–810. 
 68 Chenevard R, Hurlimann D, Bechir M, et al: 
Selective COX-2 inhibition improves endothe-
lial function in coronary artery disease. Circu-
lation 2003;  107:  405–409. 
 69 Bogaty P, Brophy JM, Noel M, et al: Impact of 
prolonged cyclooxygenase-2 inhibition on in-
fl ammatory markers and endothelial function 
in patients with ischemic heart disease and 
raised C-reactive protein: a randomized pla-
cebo-controlled study. Circulation 2004;  110: 
 934–939. 
 Krötz/Schiele/Klauss/Sohn 
 
 
 J Vasc Res 2005;42:312–324 324
 70 Title LM, Giddens K, McInerney MM, 
McQueen MJ, Nassar BA: Effect of cyclooxy-
genase-2 inhibition with rofecoxib on endothe-
lial dysfunction and infl ammatory markers in 
patients with coronary artery disease. J Am 
Coll Cardiol 2003;  42:  1747–1753. 
 71 Bea F, Blessing E, Bennett BJ, et al: Chronic 
inhibition of cyclooxygenase-2 does not alter 
plaque composition in a mouse model of ad-
vanced unstable atherosclerosis. Cardiovasc 
Res 2003;  60:  198–204. 
 72 Li X, Geary GG, Gonzales RJ, Krause DN, 
Duckles SP: Effect of estrogen on cerebrovas-
cular prostaglandins is amplifi ed in mice with 
dysfunctional NOS. Am J Physiol Heart Circ 
Physiol 2004;  287:H588–H594. 
 73 Egan KM, Lawson JA, Fries S, et al: COX-2-
derived prostacyclin confers atheroprotection 
on female mice. Science 2004;  306:  1954–
1957. 
 74 Sullivan JC, Sasser JM, Pollock DM, Pollock 
JS: Sexual dimorphism in renal production of 
prostanoids in spontaneously hypertensive 
rats. Hypertension 2005;  45:  406–411. 
 75 Hennan JK, Huang J, Barrett TD, et al: Effects 
of selective cyclooxygenase-2 inhibition on 
vascular responses and thrombosis in canine 
coronary arteries. Circulation 2001;  104:  820–
825. 
 76 Garcia Rodriguez LA, Varas-Lorenzo C, Ma-
guire A, Gonzalez-Perez A: Nonsteroidal anti-
infl ammatory drugs and the risk of myocardial 
infarction in the general population. Circula-
tion 2004;  109:  3000–3006. 
 77 Mamdani M, Rochon P, Juurlink DN, et al: 
Effect of selective cyclooxygenase 2 inhibitors 
and naproxen on short-term risk of acute myo-
cardial infarction in the elderly. Arch Intern 
Med 2003;  163:  481–486. 
 78 Bresalier RS, Sandler RS, Quan H, et al: Car-
diovascular events associated with rofecoxib in 
a colorectal adenoma chemoprevention trial. 
N Engl J Med 2005;  352:  1092–1102. 
 79 Juni P, Nartey L, Reichenbach S, Sterchi R, 
Dieppe PA, Egger M: Risk of cardiovascular 
events and rofecoxib: cumulative meta-analy-
sis. Lancet 2004;  364:  2021–2029. 
 80 Solomon DH, Schneeweiss S, Glynn RJ, et al: 
Relationship between selective cyclooxygen-
ase-2 inhibitors and acute myocardial infarc-
tion in older adults. Circulation 2004;  109: 
 2068–2073. 
 81 European Medicines Agency: Questions and 
answers on celcoxib/Cox-2 inhibitors. 
EMEA/214027/2004, http://www.cbg-meb.nl/
nl/docs/nieuws/qa-celecoxib.pdf. 
 82 Solomon SD, McMurray JJ, Pfeffer MA, et al: 
Cardiovascular risk associated with celecoxib 
in a clinical trial for colorectal adenoma pre-
vention. N Engl J Med 2005;  352:  1071–1080. 
 83 White WB, Faich G, Borer JS, Makuch RW: 
Cardiovascular thrombotic events in arthritis 
trials of the cyclooxygenase-2 inhibitor cele-
coxib. Am J Cardiol 2003;  92:  411–418. 
 84 FitzGerald GA: Cardiovascular pharmacology 
of nonselective nonsteroidal anti-infl ammato-
ry drugs and coxibs: clinical considerations. 
Am J Cardiol 2002;  89:  26D–32D. 
 85 Ott E, Nussmeier NA, Duke PC, et al: Effi cacy 
and safety of the cyclooxygenase 2 inhibitors 
parecoxib and valdecoxib in patients undergo-
ing coronary artery bypass surgery. J Thorac 
Cardiovasc Surg 2003;  125:  1481–1492. 
 86 Nussmeier NA, Whelton AA, Brown MT, et al: 
Complications of the COX-2 inhibitors 
parecoxib and valdecoxib after cardiac sur-
gery. N Engl J Med 2005;  352:  1081–1091. 
 87 White WB, Strand V, Roberts R, Whelton A: 
Effects of the cyclooxygenase-2 specifi c inhibi-
tor valdecoxib versus nonsteroidal antiinfl am-
matory agents and placebo on cardiovascular 
thrombotic events in patients with arthritis. 
Am J Ther 2004;  11:  244–250. 
 88 Farkouh ME, Kirshner H, Harrington RA, et 
al: Comparison of lumiracoxib with naproxen 
and ibuprofen in the Therapeutic Arthritis Re-
search and Gastrointestinal Event Trial (TAR-
GET), cardiovascular outcomes: randomised 
controlled trial. Lancet 2004;  364:  675–684. 
 89 Pallay RM, Seger W, Adler JL, et al: Etoricox-
ib reduced pain and disability and improved 
quality of life in patients with chronic low back 
pain: a 3 month, randomized, controlled trial. 
Scand J Rheumatol 2004;  33:  257–266. 
 90 Coulter DM, Clark DW: Disturbance of vision 
by COX-2 inhibitors. Expert Opin Drug Saf 
2004;  3:  607–614. 
 91 LeLorier J, Bombardier C, Burgess E, et al: 
Practical considerations for the use of nonste-
roidal anti-infl ammatory drugs and cyclo-oxy-
genase-2 inhibitors in hypertension and kidney 
disease. Can J Cardiol 2002;  18:  1301–1308. 
 92 Sandhu GK, Heyneman CA: Nephrotoxic po-
tential of selective cyclooxygenase-2 inhibi-
tors. Ann Pharmacother 2004;  38:  700–704. 
 93 Linton MF, Fazio S: Cyclooxygenase-2 and in-
fl ammation in atherosclerosis. Curr Opin 
Pharmacol 2004;  4:  116–123. 
 94 Rabausch K, Bretschneider E, Sarbia M, et al: 
Regulation of thrombomodulin expression in 
human vascular smooth muscle cells by COX-
2-derived prostaglandins. Circ Res 2005;  96:
e1–e6. 
 95 Radomski MW, Palmer RM, Moncada S: The 
anti-aggregating properties of vascular endo-
thelium: interactions between prostacyclin and 
nitric oxide. Br J Pharmacol 1987;  92:  639–
646. 
 96 Choi HK, Seeger JD, Kuntz KM: Effects of ro-
fecoxib and naproxen on life expectancy among 
patients with rheumatoid arthritis: a decision 
analysis. Am J Med 2004;  116:  621–629. 
 
